TriangleHLX43 DOSE 1 (2.0 mg/kg) (NCT06907615)
HLX43 DOSE 1 (2.0 mg/kg) trial for Non Small Cell Lung Cancer (NCT06907615). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced non-small cell lung cancer unsuitable for curative treatment, after platinum chemotherapy and either checkpoint treatment or appropriate targeted treatment, depending on tumor genetics. Prior topoisomerase-one treatments are excluded.
The idea: compare two doses of HLX43, given by infusion every three weeks. Its antibody binds PD-L1 and carries a drug that disrupts DNA copying. Researchers measure tumor responses and side effects. Assignment is random; both groups receive HLX43, without a placebo.
This phase 2 study plans 243 patients. Shanghai Henlius sponsors one recruiting US site in Houston.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.